NoName_3327 → 6-[4-(2-oxo-2,3-dihydro-imidazo[4,5-b]pyridin-1-yl)-piperidin-1-yl]-pyrimidine-4-carboxylic acid(1H-indazol-4-yl)-amide

HRID 74703

反応式

HRID 74703 の反応式
[O:1]=[C:2]1[NH:10][C:5]2=[N:6][CH:7]=[CH:8][CH:9]=[C:4]2[N:3]1[CH:11]1[CH2:16][CH2:15][N:14]([C:17]2[N:22]=[CH:21][N:20]=[C:19]([C:23]([OH:25])=O)[CH:18]=2)[CH2:13][CH2:12]1.[NH:26]1[C:34]2[C:29](=[C:30]([NH2:35])[CH:31]=[CH:32][CH:33]=2)[CH:28]=[N:27]1.CN(C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.[B-](F)(F)(F)F>CN(C=O)C>[NH:26]1[C:34]2[C:29](=[C:30]([NH:35][C:23]([C:19]3[CH:18]=[C:17]([N:14]4[CH2:15][CH2:16][CH:11]([N:3]5[C:4]6[C:5](=[N:6][CH:7]=[CH:8][CH:9]=6)[NH:10][C:2]5=[O:1])[CH2:12][CH2:13]4)[N:22]=[CH:21][N:20]=3)=[O:25])[CH:31]=[CH:32][CH:33]=2)[CH:28]=[N:27]1

参加物

5

実験手順

100 mg (0.29 mmol) 6-[4-(2-oxo-2,3-dihydroimidazo[4,5-b]pyridin-1-yl)-piperidin-1-yl]-pyrimidine-4-carboxylic acid and 39 mg (0.29 mmol) 1H-indazole-4-ylamine in 87 mL (0.62 mmol) TEA and 1.5 mL DMF were combined with 104 mg (0.32 mmol) TBTU and stirred overnight at RT. Then the reaction mixture was purified by preparative HPLC-MS. The product-containing fractions were combined and freeze-dried.

後処理

  1. customThen the reaction mixture was purified by preparative HPLC-MS
  2. customfreeze-dried

出典と根拠

ORDレコード
ord-b5531eca3e51478f8e8aeef3b837b76d
出典データセット
uspto-grants-2014_09
特許番号
US08829006B2

関連ノート

読み込み中…